Skip to main content
Eurobio Scientific logo

Eurobio Scientific — Investor Relations & Filings

Ticker · ALERS ISIN · FR0013240934 LEI · 969500IQEUEH806GE257 PA Manufacturing
Open in API
Filings indexed 198 across all filing types
Latest filing 2024-10-23 M&A Activity
Country FR France
Listing PA ALERS

About Eurobio Scientific

https://www.eurobio-scientific.com

Eurobio Scientific is an integrated company specializing in in vitro diagnostics (IVD). Its activities cover the entire value chain, from research and development to the manufacturing and commercialization of specialty diagnostic products. The company's core focus areas are transplantation, oncology, and infectious diseases. In transplantation, it provides reagents, software for transplant matching and chimerism monitoring, and culture media for cornea grafts. For oncology, it develops and manufactures prognostic genomic tests for breast and prostate cancer. The group also markets a comprehensive portfolio of molecular tests for detecting infectious diseases, alongside solutions for immunology, fertility, and dermatological conditions.

Recent filings

Filing Released Lang Actions
COMMUNIQUÉ RELATIF À LA MISE À DISPOSITION DES INFORMATIONS RELATIVES AUX CARACTÉRISTIQUES, NOTAMMENT JURIDIQUES, FINANCIÈRES ET COMPTABLES D’EB DEVELOPMENT DANS LE CADRE DE L’OFFRE PUBLIQUE D’ACHAT V
M&A Activity Classification · 98% confidence The document is a 'COMMUNIQUÉ' dated October 23, 2024, specifically 'RELATIF À LA MISE À DISPOSITION DES INFORMATIONS RELATIVES AUX CARACTÉRISTIQUES, NOTAMMENT JURIDIQUES, FINANCIÈRES ET COMPTABLES D'EB DEVELOPMENT' in the context of a 'OFFRE PUBLIQUE D'ACHAT' (Takeover Bid/Tender Offer) initiated by EB DEVELOPMENT for Eurobio Scientific shares. It discusses the offer price, duration, mandatory buy-out procedures (retrait obligatoire), and references the 'Note d'Information' (Information Memorandum) which has been approved by the AMF (French financial regulator). The text explicitly states that information regarding the legal, financial, and accounting characteristics of the Initiator (EB Development) has been filed with the AMF and made public today, supplementing the main Information Memorandum. This structure—an announcement detailing the availability of key documents related to a takeover bid—fits the definition of M&A Activity (TAR) or potentially a Report Publication Announcement (RPA) if it were just announcing the main document. However, since the core subject is the Tender Offer itself, including pricing and mandatory squeeze-out details, it is fundamentally related to a takeover/merger proposal. Given the options, 'M&A Activity' (TAR) is the most appropriate classification for a document detailing the terms and regulatory steps of a tender offer.
2024-10-23 French
OFFRE PUBLIQUE D’ACHAT VISANT LES ACTIONS DE LA SOCIÉTÉ EUROBIO SCIENTIFIC INITIÉE PAR LA SOCIÉTÉ EB DEVELOPMENT - Communiqué de mise à disposition du public de la note en réponse de la société Eurob
M&A Activity Classification · 98% confidence The document is a 'COMMUNIQUÉ DU 22 OCTOBRE 2024' concerning a 'OFFRE PUBLIQUE D'ACHAT' (Tender Offer) initiated by EB DEVELOPMENT targeting Eurobio Scientific SA. It specifically mentions the filing of a 'note en réponse' (response document) which has received visa approval from the AMF (Autorité des marchés financiers). This entire context—a tender offer, a response document, and regulatory approval related to a takeover bid—falls directly under the definition of M&A Activity (Merger or Takeover Bids). Code 'TAR' (M&A Activity) is the most appropriate classification, as it covers merger proposals or takeover bids.
2024-10-22 French
Eurobio Scientific: COMMUNIQUÉ DU 22 OCTOBRE 2024 RELATIF À LA MISE À DISPOSITION DE LA NOTE D’INFORMATION DANS LE CADRE DE L’OFFRE PUBLIQUE D’ACHAT VISANT LES ACTIONS DE LA SOCIÉTÉ EUROBIO SCIENTIF
Regulatory Filings Classification · 99% confidence The document is a press release dated October 22, 2024, titled "COMMUNIQUÉ DU 22 OCTOBRE 2024 RELATIF À LA MISE À DISPOSITION DE LA NOTE D'INFORMATION DANS LE CADRE DE L'OFFRE PUBLIQUE D'ACHAT VISANT LES ACTIONS DE LA SOCIÉTÉ" (Press Release of October 22, 2024, regarding the availability of the Information Note in the context of the Tender Offer targeting the Company's shares). It discusses the price, duration, and regulatory approval (AMF visa) for a Tender Offer (Takeover Bid) initiated by EB DEVELOPMENT for Eurobio Scientific shares. This clearly falls under the category of Merger & Acquisition (M&A) activity, specifically a takeover bid. The corresponding code is TAR (M&A Activity). Although it announces the availability of the 'Note d'Information' (Information Note), the core subject is the M&A transaction itself, making TAR more specific than RPA or RNS.
2024-10-22 French
Eurobio Scientific : levée de la dernière condition suspensive règlementaire au projet d’OPA initié par EB Development
Regulatory Filings Classification · 100% confidence The document is a press release dated October 16, 2024, announcing that the final regulatory condition (approval from the French Ministry of Economy regarding foreign investment control) has been lifted for a tender offer (OPA) initiated by EB Development for Eurobio Scientific. It discusses the conditions for the offer to proceed (AMF review, minimum acceptance threshold of 66.66%). This announcement relates directly to a proposed takeover bid or merger activity. According to the definitions, 'M&A Activity (Code: TAR)' covers 'Announcements and documents related to merger proposals or takeover bids.' Although it mentions the offer is subject to AMF review, the core subject is the progression of a takeover bid, making TAR the most appropriate classification over a general Regulatory Filing (RNS). The document length (5555 chars) is substantial enough that it is not merely an RPA announcing a separate document, but the substantive announcement itself.
2024-10-16 French
EB DEVELOPMENT : COMMUNIQUÉ DE PRESSE DU 30 SEPTEMBRE 2024 RELATIF AU DEPÔT D’UNE OFFRE PUBLIQUE D’ACHAT VISANT LES ACTIONS DE LA SOCIÉTÉ EUROBIO SCIENTIFIC
M&A Activity Classification · 98% confidence The document is a formal press release and filing announcement regarding a public tender offer (Offre Publique d'Achat) for the shares of Eurobio Scientific. It details the offer price, the initiator (EB Development), the concert parties, and the regulatory submission to the AMF (Autorité des marchés financiers). While it contains significant details about the offer, it is structured as a formal announcement of a filing (the 'Projet de Note d'Information') submitted to the regulator, which aligns with the definition of M&A activity (TAR) as it pertains to a takeover bid/tender offer.
2024-09-30 French
Eurobio Scientific : COMMUNIQUÉ DU 30 SEPTEMBRE 2024 EN RÉPONSE AU PROJET D’OFFRE PUBLIQUE D’ACHAT VISANT LES ACTIONS DE EUROBIO SCIENTIFIC S.A. INITIÉE PAR LA SOCIÉTÉ EB DEVELOPMENT
M&A Activity Classification · 98% confidence The document is titled "COMMUNIQUÉ DU 30 SEPTEMBRE 2024 RELATIF AU DÉPÔT DU PROJET DE NOTE D'INFORMATION" (Press release of September 30, 2024, regarding the filing of the draft information note) concerning a public tender offer (Offre Publique d'Achat - OPA) initiated by EB Development for Eurobio Scientific S.A. The text explicitly mentions the filing of the 'Projet de Note en Réponse' (Draft Response Note) with the AMF (Autorité des marchés financiers) and states that the offer documents are subject to AMF review. This document is an announcement about the filing of key documents related to a takeover bid/merger activity, specifically the response note to the tender offer. This falls directly under the definition of M&A Activity (TAR), which covers merger proposals or takeover bids. Although it is an announcement, the subject matter is the core of a takeover bid, making TAR more specific than a general RPA or RNS.
2024-09-30 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.